FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323320135> ?p ?o ?g. }

• W4323320135 abstract "Purpose This study was performed to determine the clinical biomarkers and cytokines that may be associated with disease progression and in-hospital mortality in a cohort of hospitalized patients with RT-PCR confirmed moderate to severe COVID-19 infection from October 2020 to September 2021, during the first wave of COVID-19 pandemic before the advent of vaccination. Patients and methods Clinical profile was obtained from the medical records. Laboratory parameters (complete blood count [CBC], albumin, LDH, CRP, ferritin, D-dimer, and procalcitonin) and serum concentrations of cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IFN-γ, IP-10, TNF-α) were measured on Days 0-3, 4-10, 11-14 and beyond Day 14 from the onset of illness. Regression analysis was done to determine the association of the clinical laboratory biomarkers and cytokines with the primary outcomes of disease progression and mortality. ROC curves were generated to determine the predictive performance of the cytokines. Results We included 400 hospitalized patients with COVID-19 infection, 69% had severe to critical COVID-19 on admission. Disease progression occurred in 139 (35%) patients, while 18% of the total cohort died (73 out of 400). High D-dimer &gt;1 µg/mL (RR 3.5 95%CI 1.83–6.69), elevated LDH &gt;359.5 U/L (RR 1.85 95%CI 1.05–3.25), lymphopenia (RR 1.91 95%CI 1.14–3.19), and hypoalbuminemia (RR 2.67, 95%CI 1.05–6.78) were significantly associated with disease progression. High D-dimer (RR 3.95, 95%CI 1.62–9.61) and high LDH (RR 5.43, 95%CI 2.39–12.37) were also significantly associated with increased risk of in-hospital mortality. Nonsurvivors had significantly higher IP-10 levels at 0 to 3, 4 to 10, and 11 to 14 days from illness onset ( p&lt; 0.01), IL-6 levels at 0 to 3 days of illness ( p =0.03) and IL-18 levels at days 11-14 of illness ( p &lt;0.001) compared to survivors. IP-10 had the best predictive performance for disease progression at days 0-3 (AUC 0.81, 95%CI: 0.68–0.95), followed by IL-6 at 11-14 days of illness (AUC 0.67, 95%CI: 0.61–0.73). IP-10 predicted mortality at 11-14 days of illness (AUC 0.77, 95%CI: 0.70–0.84), and IL-6 beyond 14 days of illness (AUC 0.75, 95%CI: 0.68–0.82). Conclusion Elevated D-dimer, elevated LDH, lymphopenia and hypoalbuminemia are prognostic markers of disease progression. High IP-10 and IL-6 within the 14 days of illness herald disease progression. Additionally, elevated D-dimer and LDH, high IP-10, IL-6 and IL-18 were also associated with mortality. Timely utilization of these biomarkers can guide clinical monitoring and management decisions for COVID-19 patients in the Philippines." @default.
• W4323320135 created "2023-03-07" @default.
• W4323320135 creator A5004175851 @default.
• W4323320135 creator A5004940785 @default.
• W4323320135 creator A5015876613 @default.
• W4323320135 creator A5018211068 @default.
• W4323320135 creator A5019529201 @default.
• W4323320135 creator A5021871748 @default.
• W4323320135 creator A5031951810 @default.
• W4323320135 creator A5032281309 @default.
• W4323320135 creator A5033901607 @default.
• W4323320135 creator A5044504317 @default.
• W4323320135 creator A5048191416 @default.
• W4323320135 creator A5048431264 @default.
• W4323320135 creator A5065225813 @default.
• W4323320135 creator A5070168685 @default.
• W4323320135 creator A5074181339 @default.
• W4323320135 creator A5074599472 @default.
• W4323320135 creator A5091362521 @default.
• W4323320135 date "2023-02-28" @default.
• W4323320135 modified "2023-09-27" @default.
• W4323320135 title "Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital" @default.
• W4323320135 cites W1803784511 @default.
• W4323320135 cites W2112744681 @default.
• W4323320135 cites W2123197974 @default.
• W4323320135 cites W2620241325 @default.
• W4323320135 cites W2783284840 @default.
• W4323320135 cites W2913109339 @default.
• W4323320135 cites W2945275574 @default.
• W4323320135 cites W3001118548 @default.
• W4323320135 cites W3002108456 @default.
• W4323320135 cites W3007460166 @default.
• W4323320135 cites W3009885589 @default.
• W4323320135 cites W3010538497 @default.
• W4323320135 cites W3011201358 @default.
• W4323320135 cites W3011230498 @default.
• W4323320135 cites W3011610993 @default.
• W4323320135 cites W3014001472 @default.
• W4323320135 cites W3015280639 @default.
• W4323320135 cites W3016489853 @default.
• W4323320135 cites W3016538467 @default.
• W4323320135 cites W3016846376 @default.
• W4323320135 cites W3018507926 @default.
• W4323320135 cites W3021056079 @default.
• W4323320135 cites W3021841162 @default.
• W4323320135 cites W3025160648 @default.
• W4323320135 cites W3025830962 @default.
• W4323320135 cites W3026008352 @default.
• W4323320135 cites W3032543466 @default.
• W4323320135 cites W3036625914 @default.
• W4323320135 cites W3037020655 @default.
• W4323320135 cites W3037185429 @default.
• W4323320135 cites W3038063455 @default.
• W4323320135 cites W3041960835 @default.
• W4323320135 cites W3043831218 @default.
• W4323320135 cites W3046256437 @default.
• W4323320135 cites W3049745022 @default.
• W4323320135 cites W3070884292 @default.
• W4323320135 cites W3085420778 @default.
• W4323320135 cites W3088792741 @default.
• W4323320135 cites W3091337946 @default.
• W4323320135 cites W3095535158 @default.
• W4323320135 cites W3096383810 @default.
• W4323320135 cites W3104041940 @default.
• W4323320135 cites W3109092116 @default.
• W4323320135 cites W3109926113 @default.
• W4323320135 cites W3113110940 @default.
• W4323320135 cites W3115059693 @default.
• W4323320135 cites W3116919906 @default.
• W4323320135 cites W3117854652 @default.
• W4323320135 cites W3118767253 @default.
• W4323320135 cites W3119419719 @default.
• W4323320135 cites W3129397954 @default.
• W4323320135 cites W3154092881 @default.
• W4323320135 cites W3159188075 @default.
• W4323320135 cites W3165248174 @default.
• W4323320135 cites W3170285030 @default.
• W4323320135 cites W3170583873 @default.
• W4323320135 cites W3172510702 @default.
• W4323320135 cites W3184487242 @default.
• W4323320135 cites W3186094266 @default.
• W4323320135 cites W3191207126 @default.
• W4323320135 cites W3195596939 @default.
• W4323320135 cites W3202637221 @default.
• W4323320135 cites W3217315984 @default.
• W4323320135 cites W4205922819 @default.
• W4323320135 cites W4206449744 @default.
• W4323320135 cites W4210464770 @default.
• W4323320135 cites W4210642183 @default.
• W4323320135 cites W4210750976 @default.
• W4323320135 cites W4214637964 @default.
• W4323320135 cites W4224493772 @default.
• W4323320135 cites W4231969161 @default.
• W4323320135 cites W4239371725 @default.
• W4323320135 cites W4281653388 @default.
• W4323320135 cites W4296033305 @default.
• W4323320135 doi "https://doi.org/10.3389/fimmu.2023.1123497" @default.
• W4323320135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36926338" @default.
• W4323320135 hasPublicationYear "2023" @default.
• W4323320135 type Work @default.

• next